| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive Chair & Principal Officer | Executive Chair & Principal Officer | See Remarks +5 more
3 companies
Garo H Armen is Director at INKT and has filed Form 4s across 3 companies. Garo H Armen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $22.7M at current prices.
Historically, Garo H Armen's trades have earned a middling insider score of 56/100 across 6 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +8.2%.
The biggest single holding is INKT (~$20.1M) as Director.
Garo H Armen has 159 Form 4 filings on record from February 2015 to August 2026, across 3 companies: Executive Chair & Principal Officer at Protagenic Therapeutics (PTIX), 2016–2026; Agenus (AGEN), 2015–2026; Director at MiNK Therapeutics (INKT), 2023.
The 192 reported transactions were 118 stock awards, 32 option or other derivative awards, 17 other transactions and 16 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 14 purchases worth about $2.5M and 3 sales worth about $1.6M.
The largest open-market purchase was 200,000 shares of AGEN at an average $4.03 on March 7, 2016, about $806K.
The largest open-market sale was 219,576 shares of AGEN at an average $4.59 on December 29, 2015, about $1.0M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 20,000 | $0.65 | $13,000.00 | +37.4% | - | - | |
| Aug 20, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 16,634 | $0.59 | $9,810.73 | +45.1% | - | - | |
| Aug 19, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 2,700 | $0.35 | $945.00 | +7.9% | - | - | |
| Aug 11, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 2,220 | $0.32 | $710.40 | +6.9% | - | - | |
| Aug 6, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 685 | $0.22 | $150.70 | +2.2% | - | - | |
| Aug 5, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 5,000 | $0.26 | $1,294.00 | +19.0% | +149.4% | - | |
| Jul 30, 2026 | PTIX Protagenic Therapeutics, Inc. | Executive Chair & Principal Officer | Buy | 26,291 | $0.18 | $4,805.99 | New | +291.0% | - | |
| Feb 15, 2024 | AGEN Agenus Inc | See Remarks | Buy | 500,000 | $0.65 | $324,050.00 | +396.9% | -17.6% | -73.2% | |
| May 5, 2023 | INKT Mink Therapeutics, Inc. | Director | Sell | 100,000 | $0.95 | $94,850.00 | -5.1% | +8.9% | -38.0% | |
| May 2, 2023 | INKT Mink Therapeutics, Inc. | Director | Buy | 100,000 | $0.95 | $94,850.00 | +5.3% | +110.1% | +7.0% |